Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2009

View Archived Issues

Recent Georgia Tech patent describes novel HDAC inhibitors

New MAPKAP-K2 (MK2) inhibitors reported in recent Novartis patent

Combination of YM-155, docetaxel and prednisone used in prostate cancer therapy

BIBF-1120 and BIBW-2992 may be used in combination in prostate cancer treatment

Bayer discloses prodrugs of apixaban for thromboembolic disorders

Merck & Co. discloses novel orexin receptor antagonists for insomnia

New HCV NS3/NS4 protease inhibitors reported in recent Gilead patent

PharmaMar licenses kahalalide F analogues to Marinomed

Catalyst halts enrollment into phase II trial of CPP-109 for methamphetamine addiction

MMI presents update on clinical development of GVX-3322 and ONCO-4417

2008 highlights at Elan

Anacor reports encouraging results from phase I AN-2718 trial

Pharmexa and Affitech enter into conditional merger agreement

MDV-3100 displays safety and antitumor activity in phase I/II trial for prostate cancer

Vertex to acquire ViroChem and its preclinical-stage polymerase inhibitors

FDA gives positive review of InNexus' IND plans for DXL-625 in NHL and CLL

Dronedarone reduces risk of hospitalization from cardiovascular events in atrial fibrillation

Meropenem/clavulanate combination inhibits extensively drug-resistant tuberculosis

Ferring launches degarelix for advanced prostate cancer

Quest presents positive results for its photosensitizer SL-052

4SC initiates phase IIa trial for 4SC-101 in Crohn's disease

Access announces results from a phase II ovarian cancer trial of ProLindac

CV Therapeutics reports phase I proof-of-concept data for CVT-3619

GlaxoSmithKline submits MAA for pazopanib in advanced kidney cancer

NICE refuses funding for advanced breast cancer treatment, Tyverb

Proteon initiates phase I/II PRT-201 study in hemodialysis patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...